Pellegrino Antonio, Damiani Gianluca Raffaello, Mangioni Costantino, Strippoli Davide, Loverro Giuseppe, Cappello Antonio, Turoli Scd Daniela, Corso Silvia, Tartagni Massimo, Pezzotta Maria Grazia
a Department of Obstetrics and Gynecology , Alessandro Manzoni Hospital , Lecco , Italy ;
b Department of Obstetrics and Gynecology , Azienda Ospedaliera Di Lodi , Milan , Italy ;
Acta Oncol. 2016 May;55(5):619-24. doi: 10.3109/0284186X.2015.1117134. Epub 2016 Feb 17.
Objective To evaluate the safety, local tumor efficacy and relief of symptoms of electrochemotherapy (ECT) treatment in patients affected by recurrence of vulvar cancer (VC), unsuitable for standard treatments. Methods Ten patients were recruited with histological diagnosis of recurrence of VC. Intravenous bleomycin was injected, after an accurate mapping of all lesions and ECT was performed. Response to therapy was evaluated and quality of life (QoL) was evaluated via questionnaires. Results Diagnosis stage of primary tumors, according to the FIGO system, was: four patients respectively at stage IB (40%), and at stage II (40%), one patient at stage IIIA (10%), one patient with Paget cancer (10%). Mean age was 76 years (SD ± 7) at time of enrollment. Eight patients (80%) were previously submitted to surgery and/or radio-chemotherapy. Mean treatment time was 20 (range 10-20) min. After a median follow-up of 12 (3-22) months, six patients (60%) were alive. Conclusions Objective responses (ORs) with local control of the tumor were obtained in 80%. After a mean follow-up of 12 (3-22) months six patients (60%) were alive. The favorable outcome of this study, indicates that ECT is a reliable treatment option that may improve their functioning, thus enhancing the care provided in the palliative setting.
目的 评估电化学疗法(ECT)治疗不适用于标准治疗的复发性外阴癌(VC)患者的安全性、局部肿瘤疗效及症状缓解情况。方法 招募10例经组织学诊断为复发性VC的患者。在精确描绘所有病灶后静脉注射博来霉素,然后进行ECT治疗。通过问卷调查评估治疗反应及生活质量(QoL)。结果 根据国际妇产科联盟(FIGO)系统,原发肿瘤的诊断分期为:4例患者分别处于IB期(40%)和II期(40%),1例患者处于IIIA期(10%),1例患者为佩吉特癌(10%)。入组时的平均年龄为76岁(标准差±7)。8例患者(80%)曾接受过手术和/或放化疗。平均治疗时间为20(范围10 - 20)分钟。中位随访12(3 - 22)个月后,6例患者(60%)存活。结论 80%的患者获得了肿瘤局部控制的客观缓解(OR)。平均随访12(3 - 22)个月后,6例患者(60%)存活。本研究的良好结果表明,ECT是一种可靠的治疗选择,可改善患者的功能,从而提高姑息治疗的质量。